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Abstract – Brucellosis control and eradication requires serological tests and vaccines. Effective
classical vaccines (S19 in cattle and Rev 1 in small ruminants), however, induce antibodies to the
O-polysaccharide of the lipopolysaccharide which may be difficult to distinguish from those
resulting from infection and may thus complicate diagnosis. Rough attenuated mutants lack the
O-polysaccharide and would solve this problem if eliciting protective immunity; the empirically
obtained rough mutants 45/20 and RB51 have been used as vaccines. Strain 45/20 is reportedly
unstable and it is not presently used. RB51 is increasingly used instead of S19 in some countries but
it is rifampicin resistant and its effectiveness is controversial. Some controlled experiments have
found good or absolute protection in adult cattle vaccinated orally (full dose) or subcutaneously
(reduced dose) and in one field experiment, RB51 was reported to afford absolute protection to
calves and to perform better than S19. Controlled experiments in calves, however, have shown
reduced doses of RB51 to be ineffective, full doses only partially effective, and RB51 less effective
than S19 against severe challenges. Moreover, other observations suggest that RB51 is ineffective
when prevalence is high. RB51 is not useful in sheep and evidence in goats is preliminary and
contradictory. Rough mutants obtained by molecular biology methods on the knowledge of the
genetics and structure of Brucella lipopolysaccharide may offer alternatives. The B. abortus
manBcore (rfbK) mutant seems promising in cattle, and analyses in mice suggest that mutations
affecting only the O-polysaccharide result in better vaccines than those affecting both core and
O-polysaccharide. Possible uses of rough vaccines also include boosting immunity by revaccination
but solid evidence on its effectiveness, safety and practicality is not available.
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1. INTRODUCTION
Brucella is an α Proteobacteria causing
an infectious disease of mammals that is
transmitted to humans. Ruminants and
swine are heavily infected in many areas of
the world, and wildlife is not exempt of bru-
cellosis, thus acting as a potential reservoir
for domestic livestock and a potential risk
for humans. Brucella species differ in their
hosts’ preference, physiological abilities
and cell surface structural characteristics.
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Those affecting domestic livestock are
B. melitensis (sheep and goats), B. abortus
(cattle), B. suis (swine), and B. ovis (sheep).
Because domestic ruminants and swine are
essential to the economy of millions of per-
sons, particularly in low income countries,
brucellosis is a major cause of direct eco-
nomical losses and a major impediment for
trade and exportations. Moreover, human
brucellosis is a severe and debilitating dis-
ease requiring a prolonged antibiotic treat-
ment and often leaving permanent and
disabling sequelae [13]. Thus, its eradica-
tion is a major goal of public health pro-
grams in affected countries. 
It is generally agreed that under most
conditions, vaccination is essential for the
control of bovine, ovine and caprine brucel-
losis. Controlled experiments and accumu-
lated knowledge have demonstrated that
the B. abortus strain 19 (S19) in cattle and
B. melitensis strain Rev 1 in sheep and goats
are useful vaccines [7, 17, 84]. However,
both have some undesirable traits: they are
infectious for humans [7, 77], may be abor-
tifacient when used in pregnant animals
(S19 is also of limited use in males) [17, 84],
and induce an immune response that may be
difficult to distinguish from that resulting
from infection, particularly when adult ani-
mals are vaccinated [17, 71, 84, 123]. This
is troublesome because, depending on the
challenge, no absolute protection is achieved
with these vaccines and, therefore, serolog-
ical tests do not always elucidate whether a
given animal is infected or simply shows
postvaccinal antibodies. Rev 1 shows some
additional negative traits: it is resistant to
streptomycin, one of the antibiotics of choice
used to treat brucellosis in combination
with tetracyclines [13], and it is relatively
unstable thus requiring careful standardiza-
tion to prevent variations in safety and
effectiveness [10, 17, 18, 52]. The rate of
abortion caused by S19 is low (less than 1%
in a large study involving over 10 000 cows
which were 7 to 8 months pregnant [84]) but
that of Rev 1 can be higher, particularly in
association with some of its variants [17].
The interference in the serological diag-
nosis has to be understood in the context
of the goal to be achieved by vaccination.
Individual identification, strict control of
animal movements and trade, and 100%
vaccine coverage and monitoring of the
serological and clinical status are the most
relevant requisites to achieve eradication.
In nearly all cases, this also implies to have
the means to face the costs of slaughtering
infected or suspicious animals. When prev-
alence is high or these requirements are not
met (e.g. in low-income countries), the rel-
evant point is to use the best vaccine in
terms of protection and the interference in
serological tests is not a significant problem
since the only realistic goal should be to
control the disease and to reduce the eco-
nomical losses and human contagion until
prevalence is diminished. This considera-
tion also applies to revaccination. Indeed,
revaccination with the classical vaccines
aggravates the problem of the interference
in the serological tests but the duration of
the immunity provided by these vaccines is
not known with certainty. At least for S19,
it seems to last for several pregnancies but
it is believed that revaccination increases
immunity [84] and some experiments have
shown that the best protection is obtained
by subcutaneous vaccination of calves with
S19 followed by a conjunctivally adminis-
tered booster dose [43]. Revaccination may
be necessary to control the disease in large
herds, or when the test and slaughter pro-
grams are not economically viable, as in
many low-income areas, because it reduces
the rate of abortions and the bacterial excre-
tion and transmission in infected flocks
[84]. 
When eradication is the goal of a brucel-
losis program, several strategies to lessen
the interference of S19 and Rev 1 vaccina-
tion in the serodiagnosis have been pro-
posed. They include the following: (i), to
limit vaccination to young animals; (ii), to
use a reduced dose of the vaccine in adults;
and (iii), to vaccinate by the conjunctival
route (rather than subcutaneously) (for dis-
cussions on the value of these different
4 I. Moriyón et al.
alternatives, see references [17, 56, 84,
100]). These strategies are usually comple-
mented with diagnostic tests that are highly
specific to discriminate between vaccinated
and infected animals [17, 33, 34, 36, 63, 67,
71, 72, 84, 85]. Combinations of these strat-
egies have been useful in countries with
efficient veterinarian services and rela-
tively small and well controlled herds but
they may be difficult to apply to large herds
or when extensive breeding and tran-
shumance systems exist. Vaccines devoid
of diagnostically significant antigens com-
bined with diagnostic tests that use such
antigens represent an alternative [1, 20, 38,
113]. The relevant diagnostic antigen in
B. abortus and B. melitensis infections is
the smooth (S) lipopolysaccharide (LPS)
present in field strains as well as in S19 and
Rev 1. Indeed, it is the S-LPS in these vac-
cines that complicates the diagnosis. As in
other S gram-negative bacteria, this mole-
cule has three sections: the O-polysaccha-
ride (O-PS), core oligosaccharide and lipid
A. The O-PS is the immunodominant sec-
tion to which the majority of antibodies
resulting from either infection or S19 and
Rev 1 vaccination are directed [4, 85].
2. BRUCELLA ROUGH (R) 
MUTANTS
Brucellae devoid of the O-PS are termed
rough or “R” because their colonial surface
contrasts with the glistening, smooth aspect
of those carrying S-LPS. They can naturally
be members of the R Brucella species
(B. canis and B. ovis) or mutants derived
from the S Brucella species (B. melitensis,
B. abortus and B. suis). Cultures of S bru-
cellae spontaneously dissociate to generate
mixtures of S and R colonies, the latter
formed by R mutants [9]. Owing to their
lack of antigenic O-PS, true R mutants nei-
ther induce anti O-PS antibodies nor react
with antibodies of this specificity. They
also show other outer membrane topologi-
cal and physiological changes associated
with the lack of O-PS. Manifestations of
these changes are the uptake of crystal vio-
let, the autoagglutination in acryflavin solu-
tions and the sensitivity to Brucella phages
specific for the R species [9]. Since the S →
R dissociation occurs spontaneously with a
frequency that depends on the strain and
growth conditions, repeated in vivo or
in vitro passage has been used to obtain R
vaccines. The B. abortus 45/20 and RB51
strains were developed in this way [75,
112]. Alternatively, R mutants can be gen-
erated by Molecular Genetics methods such
as transposon mutagenesis or deletion of
genes involved in S-LPS biosynthesis [3,
50, 51, 76, 78, 126, 135].
It has been known for a long time that
spontaneous Brucella R mutants are atten-
uated [116]. This attenuation has been
ascribed to the increase in both the antibody-
independent complement activation [3, 27,
44] and the sensitivity to polycationic bac-
tericidal peptides [3, 47, 74, 105]. In addi-
tion, R mutants display altered attachment
to cells [32, 48, 115]. Moreover, since the
S brucellae are intracellular parasites able
to alter the constitutive intracellular traf-
ficking (i.e. the one followed by inert par-
ticles or non-virulent Brucella) [99], other
factors related to the interplay of R mutant-
host cells must be important, an aspect that
has not been investigated so far. R mutants
have altered outer membrane topology and
LPS acylation patterns [78] and both fea-
tures could be relevant in this regard.
Live vaccines induce the appropriate
immunity against Brucella [7, 62, 138] and,
therefore, R mutants are potential brucello-
sis vaccines. Clearly, their advantage as
vaccines is that they should cause no inter-
ference in most serodiagnostic tests (but see
Sect. 7.2.1). On the contrary, they have sev-
eral potential drawbacks: (i), if infectious
for humans or other animal species, R vac-
cine infections would be unnoticed in
standard serological tests (that detect anti-
O-PS antibodies); (ii), despite the extended
opinion that antibodies do not play a role in
ruminant Brucella infections, there is a pau-
city of clear-cut experimental data on this
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point and anti-O-PS antibodies may be
important in protecting animals against
S brucellae; and (iii), R mutants may be
overattenuated and their rapid clearance
from the animals may result in an insuffi-
cient antigenic stimulus. In addition,
R mutants may not be equally efficient in
all animal species affected by smooth Bru-
cella. Point (i) could be approached by
using anti-core or anti-protein serological
tests, PCR protocols specifically designed
for the particular R mutant, or bacteriolog-
ical culture followed by typing. On the con-
trary, point (ii) is critical and the problem it
poses is intrinsic to the R vaccine approach
(see Sect. 5.1). With regard to point (iii),
it cannot be assumed in the present state
of knowledge that all R mutations (and
R mutants) result in attenuation in the nat-
ural host or, if so, that they are all equivalent
in this aspect. Both the results of compara-
tive studies [130] and the existence of the
Brucella R species virulent for their hosts
(B. canis in dogs and B. ovis in sheep) show
that not only the O-PS but also the LPS core
is implicated in Brucella virulence. Thus,
different core deficiencies may result in dif-
ferent degrees of attenuation and, therefore,
the structure, biosynthesis and genetics of
Brucella S-LPS has to be taken into account
to design the best possible R vaccine can-
didates. This aspect is developed below. 
3. STRUCTURE, BIOSYNTHESIS 
AND GENETICS OF BRUCELLA 
S-LPS
The structure of the Brucella S-LPS is
known in part. According to nuclear mag-
netic resonance studies, the O-PS is a
homopolymer of N-formyl-perosamine either
exclusively in α (1-2) linkages (for example
in B. abortus biotype 1) or in α (1-2) plus
α (1-3) in a ≥ 4:1 proportion (4:1 in
B. melitensis biotype 1) [97]. These O-PS
carry three basic types of overlapping
epitopes: C (common to all chemical types
of Brucella O-PS), M (present in those
O-PS with α (1-3) linkages) and A (present
in those O-PS with no α (1-3) linkages or
with a proportion of α (1-2) to α (1-3) link-
ages higher than 4:1). Nuclear magnetic
resonance studies also show that the S-LPS
of Yersinia enterocolitica O:9 carries a
homopolymer of N-formyl-perosamine in
α (1-2) linkages and, accordingly, it should
be identical to O-PS such as those of the
B. abortus biotype 1 [97]. It might be, how-
ever, that some aspect of these structures
has escaped the nuclear magnetic resonance
analyses because, whereas some mono-
clonal antibodies of O-PS specificity react
equally with S Brucella and Y. enterocol-
itica O:9 (Cyb epitopes), others recognize
epitopes common to all S Brucella but not
to Y. enterocolitica O:9 (Cb epitopes) [24,
37], strongly suggesting subtle structural
differences. The structure of the Brucella
LPS core is largely unknown and qualita-
tive studies show 3-deoxy-D-manno-2-
octulosonic acid, mannose, glucose, glu-
cosamine and quinovosamine as the main
sugars (reviewed in references [82, 130]).
That of lipid A has been partially elucidated
[103, 130].
The synthesis of LPS in Brucella is
largely unknown but the genetic evidence
available [31, 51, 96] is fully consistent
with a mechanism similar to that existing in
some of the best studied gram-negative bac-
teria [54, 64, 104]. First, lipid A is synthe-
sized on the inner face of the cytoplasmic
membrane. Second, through the sequential
action of glycosyltransferases, sugars are
added to lipid A until the core oligosaccha-
ride is completed. These two pathways are
intermingled since two 3-deoxy-D-manno-
2-octulosonate residues are added before
lipid A synthesis is finished. On the con-
trary, the O-PS is synthesized in an inde-
pendent pathway and, once its biosynthesis
is carried through, it is linked to the acceptor
sugar of the completed lipid A-core. Depend-
ing on the particular O-PS, there are three
known types of mechanisms of synthesis,
and that of Brucella belongs to the so-called
ABC transporter-dependent (or wzy-inde-
pendent) type [51, 64]. In this pathway
(Fig. 1), a lipid carrier (undecaprenol
6 I. Moriyón et al.
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pyrophosphate) on the cytoplasmic side of
the membrane is first primed with an amino
sugar by the WecA protein. Then, O-PS
sugar units are inserted successively at the
non-reducing end (i.e. the “tip” of the grow-
ing polysaccharide) by glycosyltransferases.
Finally, the ABC proteins translocate the
amino sugar-O-PS (possibly still linked to
the undecaprenol) to the periplasmic side of
the membrane where a ligase (WaaL) binds
the amino sugar-O-PS to the completed
lipid A-core. Thus, when the synthesis of
the core is blocked, the O-PS is generally
not incorporated to the LPS. In addition
to the lipid A, core, and O-PS pathways,
there are subsidiary pathways that provide
the necessary nucleotide-sugar precursors.
Some of them are exclusive to LPS biosyn-
thesis whereas others are housekeeping
pathways.
The more recent nomenclature for the
genes coding for the enzymes of LPS syn-
thesis [104] uses four letters:1 (i), lpx* for
those involved in the early steps of lipid A
synthesis; (ii), wa** for those involved in
the late steps of lipid A synthesis, in core
synthesis and in the ligation of the amino
sugar-O-PS to the lipid A-core (waaL);
(iii), wb** for those involved in the OP-S
synthesis; and (iv), wz** for those involved
in OP-S processing (for example, wzm/wzt
are the genes coding for the ABC transport-
ers such as those acting on Brucella OP-S).
The genes coding for the enzymes belong-
ing to the precursor pathways follow a con-
ventional nomenclature (for example man*
for mannose biosynthesis, per for pero-
samine synthetase, etc.) even though they
functionally belong to LPS pathways.
Sometimes there are two different genes for
the same enzymatic function as there can be
two pathways for the same sugar when it is
present in both the core or the O-PS and, in
this case, subindexes are used (for example,
manBcore and manBOAg for the phospho-
mannomutases of core and O-PS [O Anti-
gen] mannose synthesis). At least sixteen
genes have been proven to be involved in
Brucella LPS synthesis by analysis of the
corresponding mutants (Tab. I) and, as in
many bacteria, most of the O-PS ones are
clustered in a region (the Brucella wbk
region; Fig. 2). Although mutations in some
genes outside wbk also bring about an R
phenotype, their assignation to the core or
O-PS pathways is less clear (Tab. I). As
judged by the analyses derived from the
complete sequence of the B. melitensis and
B. suis genomes [31, 96], Brucella LPS
genes are scattered in both chromosomes
with the exception of the wbk region
(Tab. I).
From the above-summarized data, it fol-
lows that B. melitensis, B. abortus and
B. suis R strains should result from muta-
tions in some wa** genes (including
waaL), in all wb** genes, in the wzm/wzt
genes, and in genes of the pathways that
lead to precursors of core and O-PS sugars
(for example manBcore and per, respec-
tively). But for the absence of an O-PS
linked to the remaining LPS molecule, it
can be predicted that not all these mutants
are equivalent and they can be hypotheti-
cally grouped as follows: (i), R mutants that
have a complete lipid A-core plus a cyto-
plasmic O-PS, the incorporation of which
to the LPS is blocked (at least the wzm/wzt
and possibly the waaL mutants); (ii), R
mutants that have a complete lipid A-core
but no O-PS (mutants in wb** glycosyltrans-
ferases, in wecA, and in genes coding for
enzymes necessary for the synthesis of
some precursors, such as manBOAg, gmd
and per) and (iii), R mutants that have pro-
gressive deficiencies in the core and that
may or may not accumulate cytoplasmic
O-PS (mutants in some wa** genes and in
some precursor genes such as manBcore).
Mutants of each of these three groups have
in fact been described [50, 51, 76, 78, 126],
and the question then arises as to what
extent they are equivalent in attenuation
and immunizing abilities. 
1 In what follows, asterisks represent any letter,
and the last one is capitalized.
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The above picture is complicated by the
fact that S brucellae carry a second surface
polysaccharide (the native hapten) akin to
the O-PS with which it shares the sugar
backbone [12] but from which it differs in
the degree of formylation (50–60% instead
of over 90% for the O-PS) (M. Staaf, G.
Widmalm, A. Weintraub, A. Cloeckaert,
A.P. Teixeira-Gomes, R. Díaz, E. Moreno,
and I. Moriyón, unpublished results). The
defects in perosamine synthesis prevent the
synthesis of this polysaccharide but pres-
ently it is not known or can be predicted
how defects in later steps may affect its
location and expression.
4. BRUCELLA R MUTANTS 
DEVELOPED FOR VACCINE 
STUDIES
4.1. B. abortus 45/20
This R vaccine was obtained after twenty
passages in guinea pigs of a field isolate
(B. abortus strain 45) in 1938. However,
the original 45/20 strain was reported to
revert to S pathogenic forms when injected
into cattle [28, 84, 125]. Alton [5] reports
of experiments with several 45/20 stocks
which, after repeated passages in guinea
pigs, showed either S-intermediate and R
colonies or only R forms depending on the
origin of the stocks. This suggests that the
original strain contained in fact several dif-
ferent clones so that the S-intermediate
ones became selected when injected into
cattle. Also, it seems likely that different
laboratory variants of this strain have coex-
isted for years. A 45/20 stock maintained in
the laboratory of the authors since 1982 and
originally obtained from G. Dubray (Insti-
tut National de la Recherche Agronomique,
Tours, France) is stable but it produces
small amounts of O-PS of possibly an
anomalously polymerized and reduced
number of sugar units ([48], and E. Moreno
and I. Moriyón, unpublished results). The
genetic defects in this strain are unknown
and the vaccine is not presently marketed.
4.2. B. abortus RB51
Strain RB51 is a spontaneous R mutant
selected after repeated in vitro passages of
B. abortus 2308 (United States Department
of Agriculture challenge strain) on media
containing rifampin and penicillin [112].
Selection was performed using the crystal
violet and acryflavin tests. RB51 carries an
IS711 spontaneously inserted into wboA
(putatively coding for a glycosyltransferase)
[131]. However, a wboA transposon mutant
obtained from strain 2308 is not as attenu-
ated as RB51 [76] and the protection
afforded by wboA mutant vaccines in mice
is better than that provided by RB51 (see
Sect. 6.1.3), which shows that RB51 carries
additional and unknown defects. In the
complete sequence of B. melitensis, B. suis
and B. abortus genomes (an annotated
B. abortus complete sequence is not avail-
able) wboA maps outside of the main wbk*
O-PS genetic region (Tab. I). RB51 accu-
mulates small amounts of O-PS [25]. This
is noteworthy because, accepting that the
current model of the B. abortus LPS struc-
ture is correct, mutation in a wb** gene
should prevent O-PS synthesis. Comple-
mentation of RB51 with wboA increases
O-chain expression but does not restore the
S phenotype [132] suggesting that other LPS
genes are affected. In addition, although
sodium dodecyl sulfate (SDS) polyacryla-
mide gel electrophoresis (SDS-PAGE)
migration patterns have been interpreted to
mean that RB51 carries a LPS with a com-
plete core, chemical analyses show that this
R-LPS contains 2.5 times less mannose
than the B. abortus RA1 wboA mutant [76].
The presence in RB51 of additional muta-
tions in genes not involved in LPS synthesis
cannot be excluded either.
On the contrary to 45/20, RB51 is stable
[112] and it is currently being used in some
countries instead of S19. Although it should
show very low or no virulence in humans,
there is little information on this point and
there has been at least one case of RB51
infection in a veterinarian demonstrated by
bacteriological isolation and typing of the
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strain [134]. It has to be stressed that RB51
is resistant to rifampin, an antibiotic cur-
rently used in the groups of brucellosis
patients that cannot be treated with strepto-
mycin (pregnant women, children of young
age, and endocarditis and neurobrucellosis
cases) [13].
4.3. Genetic constructs derived 
from RB51
RB51 has been used as the starting strain
in two genetic manipulations. First, the
wboA defect has been complemented with
a functional wboA gene to generate strain
RB51Wboa [132]. This strain keeps the
R phenotype manifested in the crystal
violet and acryflavin tests, but expresses
increased amounts of O-PS which by immu-
noelectronmicroscopy seems to accumulate
in the cytoplasm. However, at least part of
this O-PS may be linked to a lipid to give
an immunogenic form because it migrates
in SDS-PAGE and vaccination of mice with
RB51WboA elicits IgG antibodies of at least
C specificity. Second, the Brucella Cu/Zn
superoxide dismutase gene has been intro-
duced in RB51 to obtain strain RB51SOD
which overexpresses (tenfold) this protein
[133]. The aim of this manipulation is to
increase the expression of a Brucella anti-
gen and a possible virulence factor on the
RB51 background. 
4.4. wboA mutants other than RB51
Mutants in this putative glycosyltrans-
ferase gene (Tab. I) have been obtained
from B. melitensis 16M and B. suis 2579 by
allelic exchange to generate the strains
VTRM1 and VTRS1, respectively. Both
are kanamycin resistant since they carry a
Tn5 element [135]. Although, it was origi-
nally named rfbU, blast analysis of the Sal-
monella typhi RfbU prototype against the
B. melitensis genome shows the highest
similarity (E value 1e–16) with WbkA (see
Tab. I), and more recently the gene has been
renamed wboA [113] (E value for RfbU ver-
sus WboA is only 2e–04). The VTRM1 and
VTRS1 mutants are stable in mice, lack
reactivity with monoclonal antibodies of C
specificity and have an R phenotype but
they have not been tested for the absence of
core defects or expression of cytoplasmic
O-PS. 
4.5. Mutants in the wbk region
Several mutants in this cluster of O-
polysaccharide genes have been described
[50, 51, 78], and two have been analyzed
as vaccines. B. abortus 2.17 and B. abortus
9.49 have been obtained from B. abortus
2308 by transposon mutagenesis and selec-
tion for polymyxin B sensitivity, and they
carry the Tn5 insert (they are kanamycin
resistant) in wbkA and per, respectively
[78]. Both are resistant to the S Brucella
specific phages, sensitive to the R Brucella
specific R/C phage and positive in the
crystal violet and acryflavin tests and do
not express O-PS. As judged by the elec-
trophoretic mobility (Tab. I) and the reac-
tivity with monoclonal antibodies specific
for the inner and outer core epitopes [107],
the R-LPS of both mutants keeps an intact
core oligosaccharide [78], which is con-
sistent with the position of wbkA in the
major O-PS genetic region (Fig. 2) and the
putative role of Per. 
4.6. Mutants in genes affecting the LPS 
core structure
4.6.1. B. abortus B2211 pgm
This mutant carries a gentamicin-resist-
ance non polar cassette in the pgm (phos-
phoglucomutase) gene of B. abortus 2308
[126]. It is resistant to the S-Brucella spe-
cific Tb phage and carries R-LPS as judged
by SDS-PAGE analysis. The central role
of this enzyme in the synthesis of hexoses
derived from glucose makes pleiotropic
effects on the synthesis of oligo- and
polysaccharides likely and, at least, the
pgm mutant is also blocked in the synthesis
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of the periplasmic β(1,2) cyclic glucans
[19, 57]. Mutation in the homologous gene
of B. melitensis causes a core defect as
judged by the electrophoretic mobility in
SDS-PAGE of its R-LPS (Tab. I).
4.6.2. B. abortus mutant 80.16 wa** 
This is a mutant in a putative glycosyl-
transferase gene involved in core synthesis
(hence its provisional denomination as
wa**) (Tab. I) as shown by SDS-PAGE and
Western blots with monoclonal antibodies
to core epitopes [78]. Like B. abortus 9.49,
it was obtained by Tn5 transposon muta-
genesis of B. abortus 2308 and selection for
polymyxin B sensitivity. This mutant is
resistant to kanamycin, to the S brucellap-
hages, sensitive to phage R/C and does not
express O-PS. A remarkable feature of the
R-LPS of this mutant is that while keeping
a fully reactive outer core epitope, it shows
a reduced reactivity with monoclonal anti-
bodies to the inner core epitope suggestive
of a branch in the inner core in which the
missing sugar(s) would be placed. 
4.6.3. B. abortus manBcore mutants
Two different mutants in this gene, both
from B. abortus 2308, have been described:
the rfbK mutant [2, 3] and mutant 55.30
[78]. The mutated gene (formerly rfbK but
manB according to recent nomenclature
[104]) putatively codes for a phosphoman-
nomutase and is thus predicted to be
involved in the synthesis of mannose-1-P.
Although mannose-1-P is a precursor of
perosamine (the O-PS sugar), the mutated
gene is not homologous to the manB of the
wbk region (manBOAg, Fig. 2) and its loca-
tion (Tab. I), the lack of reactivity with
monoclonal antibodies of outer core specif-
icity and the SDS-PAGE profile of the cor-
responding R-LPS (Tab. I) show that it acts
as a manBcore [78]. This is consistent with
the presence of mannose in the core of
B. abortus (see Sect. 3).
5. THE EVALUATION 
OF BRUCELLA VACCINES
5.1. The mouse model
Mice are relatively resistant to brucello-
sis and many unspecific stimuli, stress and
inflammatory responses can induce some
degree of resistance or increase susceptibil-
ity. Because of the high costs and long time
span of the experiments in natural hosts,
however, mice have been used as a prelim-
inary step in the analyses of vaccines
against brucellosis [2, 3, 60, 78, 79, 112,
120]. Although there are variations in the
protocols used by the different authors, a
method has been standardized for the qual-
ity control of the classical S live anti-Bru-
cella vaccines and it is currently accepted
by the OIE and the European Union [10,
11]. The method allows the prediction of
the safety and immunogenicity of Rev 1 and
S19 seed stocks on the values of two com-
plementary parameters: the residual viru-
lence (i.e., the persistence in the spleen
determined as the Recovery Time 50
[RT50] of the vaccine) and the immuno-
genicity (i.e., the ability to protect against
a challenge with a virulent strain deter-
mined as the number of virulent bacteria in
the spleen). These parameters are measured
under a tightly defined set of experimental
conditions, including the number and breed
of the animals, route of inoculation, doses
(vaccine and challenge), challenge strain,
and time intervals at which the number of
colony forming units (CFU) in spleens are
determined [18, 52]. This particular mouse
model discriminates both insufficiently
attenuated and ineffective Rev 1 and S19
from useful seed stocks by using as controls
the RT50 and immunogenicity of reference
stocks of the respective vaccines known to
perform satisfactorily in sheep and cattle.
These ideas have been extrapolated to the
evaluation of R vaccine candidates and it
has been found that different R mutants
show differences in splenic growth curves
[3, 78] and immunogenicity [78]. However,
the underlying assumption that, like S strains,
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differences in splenic growth curves and
CFU after a challenge reflect differences in
virulence/attenuation and immunogenicity
of R vaccines in the natural host has not
been put to test. In addition, on the contrary
to what occurs with the S vaccine seed
stocks, there is no experience with different
R vaccines in the field and, therefore, there
are no standards to define optimal RT50 and
immunogenicity in the mouse model. A
reasonable assumption is that an R mutant
showing RT50 and immunogenicity values
similar to those of the S vaccines should be
a promising vaccine candidate for testing in
the natural host. It is possible to obtain
RT50 values with some R mutants similar
to those of S vaccines by increasing the
number of CFU administered (see below),
but the interpretation of the immunity is
not straightforward. Experience shows that
protection with respect to unvaccinated
controls is easily achieved in mice using
killed vaccines or antigens (such as S-LPS)
that have little or no efficacy in the natural
hosts. Thus, when evaluating the R vaccine
candidates, it is always important to include
not only unvaccinated but also Rev 1 or S19
vaccinated mice as controls, and to compare
the protection against these “gold” stand-
ards. Under these conditions, at least when
the challenge is an S virulent B. abortus or
B. melitensis strain, the immunity gener-
ated by R vaccines is always lower than that
observed with the S vaccines [53, 78, 120,
135]. Indeed, S vaccines elicit antibodies to
the S-LPS but, whereas the role of cellular
immunity in protection is clear, that of anti-
S-LPS antibodies against Brucella infec-
tion in natural hosts has been a matter of
controversy for many years. Despite the
extended notion that it is a proven fact that
antibodies are not relevant in protection,
there is a paucity of experimental data.
Maternal antibodies may play a role in pro-
tecting calves born within infected herds
[123] but animals vaccinated by the con-
junctival route, a method eliciting a shorter
and less intense antibody response, are as
protected as those vaccinated subcutane-
ously [17, 84, 100]. On the contrary, it is
clear that anti S-LPS antibodies are by
themselves protective in mice [58, 80, 101,
122] mainly because, as opposed to non
opsonic routes, capture by Fc or C3b
dependent routes lead to a quick destruction
of Brucella by professional phagocytes
[99]. Thus, it is not known to what extent
the S versus R vaccine comparisons in mice
can be extrapolated to the natural hosts. It
seems likely, however, that the model is not
so biased when used to compare different
R vaccines.
5.2. Experiments in cell lines
For obvious reasons, the usefulness of
cell lines and explants is limited to an eval-
uation of some aspects of the virulence of
R mutants. Some R mutants, such as the
B. suis manBcore have unpaired ability to
multiply in human monocytic THP1 and
HeLa cell lines [46], and the B. abortus
B2211 pgm mutant is also attenuated in
HeLa cells [126]. On the contrary, the
B. melitensis B3B2 per mutant seems to
multiply normally in an immortalized
bovine macrophage cell line [50]. It is not
possible to know whether these are strain or
methodological differences and the obser-
vations are presently of little use in the
design of R vaccines. However, it has been
shown that S19 differs from virulent B. abor-
tus in that, although both are detected first
in early endosomes and then in autophagic
vacuoles of HeLa cells, the vaccine is even-
tually degraded in lysosomes, whereas the
virulent strain is not [98]. This suggests a
characteristic pathway for, at least, one of
the vaccines with proved efficacy in the nat-
ural host and opens the possibility of com-
paring the intracellular behavior of LPS
mutants against that of virulent and refer-
ence vaccine strains as a means to eliminate
both non attenuated and overattenuated
vaccine candidates. Thus, future studies on
the intracellular behavior of the different R
mutants in professional and non profes-
sional phagocytes may be of help to select
vaccine candidates.
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5.3. Experiments in the natural host
Evaluations in the natural hosts can be
performed in controlled experiments and
in the field.
5.3.1. Controlled experiments
Controlled experiments are based on the
comparison of the clinical, bacteriological
and serological findings in homogeneous
(breed, age sex and reproductive status)
groups of randomly selected animals in
numbers adequate for statistical analysis. In
these experiments, it is possible to strictly
control the preparation, dosage and appli-
cation of the vaccine. Controls include
unvaccinated animals and, ideally, animals
vaccinated with the reference vaccine. The
efficacy is determined after a time span that
varies depending on the purpose of the
experiments. The animals are usually chal-
lenged during the middle (5–6 months for
cattle, and 2–3 for sheep and goats) of the
first pregnancy so that this time span varies
depending on whether the animals are vac-
cinated before or shortly after sexual matu-
rity. It is also important to use a reference
strain to prepare the challenge. B. abortus
2308, B. abortus 544, B. melitensis 16M,
B. melitensis H38, and B. ovis PA are the
strains commonly used for this purpose.
However, perusal of the literature suggests
that strains 544 and H38 are more virulent
than their species counterparts. The animals
are usually challenged conjunctivally because
it is thought that mucosae represent the nor-
mal route of entry, and the dose is adjusted
so that a large number of unvaccinated con-
trols become infected, ideally 99%. This is
a critical point since it is obvious that under
conditions resulting in a relatively low pro-
portion of infected controls even poor
vaccines may show efficacy and, on the
contrary, very strong challenges resulting
in 100% infected controls are likely to mean
an overdose of unknown intensity thus
obscuring the performance of good vac-
cines. When this happens, indirect indexes
such as the degree of colonization of target
organs may be useful. Even though an over-
challenge makes the assessment of a single
vaccine difficult, it is clear that in compar-
ative experiments differences are better
revealed when stringent challenges are
used.
Monitoring the results of controlled
experiments is done by bacteriological pro-
cedures. This implies a thorough bacterio-
logical search for the challenge strains
Brucella in the target organs using the
appropriate reference media so that quanti-
tative or semi-quantitative data are obtained
for each animal (i.e. bacteria below the
threshold detection level, approximate
number of bacteria per organ, number of
organs colonized, etc.). Obviously, these
are very expensive and laborious experi-
ments also requiring biosafety level 3 con-
tainment facilities but they provide a solid
evidence to draw conclusions, provided it is
kept in mind that they relate directly to the
experimental conditions.
5.3.2. Observational field studies
Since observational field studies should
represent the “real” test, they are consid-
ered sometimes as the method of choice.
However, brucellosis is a complicated dis-
ease and field evaluations may be easily
biased by a number of confounding fac-
tors. These include, at least, (i), the selec-
tion of the animals to be vaccinated, which
should not be done solely on the basis of
serological tests; (ii), the breed, age, sex
and reproductive status of the animals;
(iii), the prevalence, which modulates the
chances of a given animal to be exposed
and the intensity of the challenge2; (iv), the
2 The higher the prevalence, the more abortions
and shedders. This means not only an increased
chance of a contact with contaminated materials
(abortions, placenta, milk, water, food, etc.) but
also higher numbers of bacteria. This is so because
the numbers of viable brucella in these materials
decay with time and, therefore, the probability of a
contact with high numbers of viable brucella
increases when there are many of such contamina-
tions or they happen more often.
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method for preparing and applying the vac-
cine under field conditions and its standar-
dization; (v), the general management
conditions (i.e., size of the flocks, breeding
systems, feeding and milking practices,
handling of potentially infected animals,
incidence of other diseases, etc.); (vi),
basic aspects of study design such as the
use and type of control groups, particularly
when other health measures are simulta-
neously being taken (for example, removal
of serologically or clinically positive ani-
mals) and when conclusions with regard to
alternative vaccines are sought; (vii), the
system of monitoring the disease (see
below); and (viii), the time span of the
observational study, which should be long
enough to establish firm conclusions.
Knowledge by the farmers (and resear-
chers) of the vaccine status of the groups of
the animals may also be a source of bias
since it may influence the management of
the animals. Ideally, a double blind system
should be implemented in these studies.
Obviously, it is very difficult to strictly
control all these factors, or implement all
controls under natural conditions. Never-
theless, adequate observational field stu-
dies are a final and necessary step if
supported by the controlled studies.
Further limitations of the field studies
come from the means available to monitor
the effect of the vaccine. This can be per-
formed serologically (but see point [vi]
above) taking into account the specificity
of the tests (i.e. their ability to differentiate
vaccinated from infected animals), and
also by bacteriological methods. The latter
are totally specific but are limited in sensi-
tivity both intrinsically and, in the field
experiments, by the availability of samples
(mostly aborted fetuses and milk). The rate
of abortion as a clinical index of the dis-
ease may also be useful provided the etio-
logical agent is identified in all or a
significant number of the cases. Indeed, a
reliable estimation of this index is very dif-
ficult to obtain when breeding is extensive
and reports from farmers must be taken
with caution. Moreover, abortion is not a
constant clinical sign of infection and it has
been estimated that about 20% of infected
cattle never abort, and that about 80% of
those that abort do so only once, some
twice in successive pregnancies but rarely
more than twice [29]. This means that an
assessment of the rate of abortions in the
whole flock may be masking the real effect
of the disease because, if the disease is
chronically established, abortion typically
affects first pregnancy replacements. It is
also important to keep in mind that if erad-
ication is the goal, the use of this index by
itself may be misleading. A decrease in the
rate of abortions does not necessarily mean
that animals are not infected and it is
known that non aborting infected mothers
act as shedders and carriers transmitting
the disease both to naive animals and con-
genitally [102]. A reduction in the rate of
abortion can be attained after massive vac-
cination with S19 not accompanied by
removal of infected animals or other pro-
phylactic measures and long experience
shows that, although the economical impact
of the disease is reduced, it results in a per-
petuation of brucellosis in the flock with
continuous losses and, if vaccination is
stopped, outbreaks.
6. R MUTANTS EVALUATED 
IN MICE
6.1. Against B. abortus
6.1.1. RB51
The persistence in the spleen and the pro-
tection afforded by RB51 and S19 against
B. abortus were first compared in mice by
Stevens et al. [120], and a summary of these
experiments is presented in Table II. The
results show that RB51 is more attenuated
in mice than S19, with shorter persistence
times even at a 100 fold higher dose. In
these experiments, the protection generated
by RB51 was consistently and significantly
lower than that of the reference S vaccine
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(Tab. II). These results are similar to those
of other studies performed under slightly
different conditions [60, 132] (see also
Tabs. IV and V). RB51 has also been com-
pared in the mouse model with other R
strains most often with unfavorable results
(see Sects. 6.1.3 and 6.1.4). Reasons for this
lay probably in the accumulation in RB51
of more than a single mutation in LPS genes
(see Sects. 4.2 and 6.1.3) and/or elsewhere
leading to excessive attenuation.
6.1.2. RB51WboA and RB51SOD
Neither RB51WboA nor RB51SOD dif-
fer in their persistence in the spleens of
BALB/c mice (about 6 weeks for a 6 ×
108 CFU intraperitoneal dose in the exper-
iments described in the references [132,
133]). In addition, both afford significantly
better protection than RB51 in BALB/c
mice, in particular RB51WboA (Tab. III).
Although less than S19, RB51WboA
induces significant amounts of anti-S-LPS
IgG antibodies which are known to be pro-
tective (see Sect. 5.1). Thus, RB51WboA
could be a better vaccine than RB51 but the
interference in the serodiagnosis would
have to be examined.
6.1.3. wboA mutants other than RB51
Mutants B. melitensis VTRM1 and
B. suis VTRS1 were examined in mice by
Winter et al. [135]. Inoculated intrave-
nously at 5 × 104 CFU, both persist longer
than 8 weeks in the spleens of BALB/c
mice, with splenic multiplication curves
similar to that of Rev 1. They were tested
against B. abortus, B. melitensis and B. suis
(see below) in comparison with the stand-
ard S vaccines and RB51, and a summary
of the experiments in which B. abortus
2308 was used as the challenge strain is
presented in Table IV. It can be seen that
the protection afforded by VTRM1 and
VTRS1 is lower than that obtained with
S19 but also that, despite the large differ-
ences in dose, both strains perform slightly
better than RB51. Although not always sta-
tistically significant, this difference with
respect to RB51 was consistently observed
in experiments with other challenge strains
[135]. As mentioned above, these results
Table II. Comparison of vaccines S19 and RB51 against B. abortus infection in BALB/c mice1.
Vaccine Dose 4 Persistence (weeks) 5
X log10 CFU in spleen ± SD (units of protection) 
at postvaccination week2,3:
12 16 20
S19 4.2 × 106 >16 2.3 ± 0.6 (4.4) a 1.4 ± 0.6 (4.5) a 1.2 ± 0.4 (5.7) a
RB51 5.7 × 106 = 8 4.6 ± 0.4 (2.1) a,b 3.3 ± 0.6 (2.6) a,b 5.3 ± 0.4 (1.6) a,b
RB51 4.6 × 108 8–12 4.9 ± 0.5 (1.8) a,b 4.2 ± 0.4 (1.7) a,b 4.9 ± 0.4 (2) a,b
Saline 6.7 ± 0.3 5.9 ± 0.3 6.9 ± 0.1
1 Adapted from Stevens et al. [120].
2
 Lots of mice (n = 24) were inoculated intraperitoneally with each vaccine. Twelve, 16 or 20 weeks after
vaccination, 8 mice from each lot were challenged by the same route with B. abortus 2308 (2.4 × 104 to
4.5 × 104 CFU/ mouse), sacrificed 2 weeks after challenge, and CFU in the spleen was determined. Units
of protection were calculated by subtracting the mean log10 CFU in the spleens of vaccinated mice from
the mean log10 CFU in the spleens of saline inoculated mice.3
 Statistical significance (Fisher protected least significant differences test) with respect to saline inocu-
lated mice: a P < 0.05; with respect to the S19 inoculated mice b P < 0.05.
4
 CFU administered intraperitoneally.
5
 Lots of 32 mice were vaccinated and slaughtered (n = 8) 2, 4, 8, and 12 weeks later. The results are
expressed as the time at which no animal showed a positive spleen count.
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suggest that RB51 carries mutations in
genes other than wboA. 
6.1.4. Mutants in the wbk region
The experiments carried out with these
mutants (and also with LPS core mutants)
are summarized in Table V. It is notewor-
thy that both 2.17 wbkA and 9.49 per show
the same RT50 as the reference vaccine
S19 (however, the doses were different).
This result is consistent with the observa-
tion by Godfroid et al. [50] that B. meliten-
sis per mutants keep the ability to multiply
in cultured bovine macrophages. With
regard to protection, there are three obvi-
ous comments on the data of Table V.
First, S19 is the best vaccine in terms of
Table III. Evaluation of RB51WboA and RB51SOD in comparison with RB51 as vaccines against
B. abortus infection in BALB/c mice.
Experiment 
[reference]
Vaccine Dose 1 Anti-S-LPS
antibody 2
X log10 CFU in spleen ± SD (units of 
protection): 3,4
1 [132] RB51 3 × 108 – 5.0 ± 0.2 (0.7) a
RB51WboA 3 × 108 +++ 0.5 ± 0.0 (5.1) b
Saline 5.7 ± 0.1 
2 [133] RB51 4 × 108 – 4.6 ± 0.5 (0.8)
RB51SOD 4 × 108 – 2.9 ± 1.8 (2.5) c
Saline – 5.4 ± 0.3 
1 CFU administered intraperitoneally.
2
 The results are expressed as follows: –, no antibody; +++, amount of antibody generating 50% of the
OD generated by sera from S19 infected mice in an ELISA-IgG.
3
 Lots of BALB/ c mice (n = 5 in Experiment 1 and n = 7 in Experiment 2) were inoculated intraperito-
neally with the vaccine strain or saline, challenged by the same route with B. abortus 2308 7 weeks after
vaccination, and spleen CFU were determined 2 weeks later. Units of protection were calculated by sub-
tracting the mean log10 CFU in the spleens of vaccinated mice from the mean log10 CFU in the spleens
of saline inoculated mice.
4
 Statistical significance (Student t test) with respect to saline (Experiment 1): a P < 0.001; b P < 0.0001;
or with respect to RB51 (Experiment 2): c P < 0.01.
Table IV. Evaluation of mutants VTRM1 and VTRS1 in comparison with RB51 and S19 as
vaccines against B. abortus infection in BALB/c mice1.
Vaccine Dose (route) 2 X log10 CFU in spleen ± SD (units of protection): 3,4
S19 5 × 103 (IV) 3.42 ± 0.57 (3.24) a
RB51 5 × 108 (IP) 5.78 ± 0.58 (0.88) b
VTRM1 5 × 104 (IV) 5.40 ± 0.68 (1.26) b
VTRS1 5 × 104 (IV) 5.25 ± 0.95 (1.41) c
None 6.66 ± 0.35
1
 Data are from Winter et al. [135].
2
 CFU administered intravenously (IV) or intraperitoneally (IP).
3
 Lots of BALB/ c mice (n = 5) were inoculated with the vaccine or left unvaccinated, challenged IP with
B. abortus 2308 (5 × 104 CFU/ mouse) 8 weeks after vaccination and spleen CFU were determined two
weeks later. Units of protection were calculated by subtracting the mean log10 CFU in the spleens of vac-
cinated mice from the mean log10 CFU in the spleens of non vaccinated mice.4
 Statistical significance (Student t test) with respect to non vaccinated mice: a P < 0.001; b P < 0.01; 
c
 P < 0.05.
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residual virulence (RT50) and immuno-
genicity. Second, 2.17 wbkA and 9.49 per
perform satisfactorily when these two
parameters are considered, and these wbk
mutants are the only protective R vaccines
under the experimental conditions. Third,
neither RB51 nor the mutants with core
defects protect significantly.
6.1.5. Mutants in genes affecting the LPS 
core structure
Two of these mutants have been ana-
lyzed in comparison with the wbk mutants
(Tab. V). B. abortus 55.30, the manBcore
mutant carrying the most severe core defect
(Tab. I), shows an RT50 similar to that of
9.49 per and 2.17 wbkA. This is not in con-
tradiction with the report by Allen et al. [3]
that a B. abortus manBcore (rfbk) mutant is
practically avirulent in Balb/c mice because
these authors used a much lower dose in
their experiments. The inner core-deficient
80.16 wa** mutant shows a shorter RT50(similar to that of RB51), and a comparison
with the manBcore mutant suggests that not
all core sections are equally important in
virulence. Explanations for this could relate
to different interactions with bactericidal
polycations, increased in 80.16 wa** with
respect to 55.30 manBcore [78]. The failure
of these two core mutants to induce signif-
icant protection has been pointed out above.
The contrast between the good RT50 of
mutant 55.30 manBcore and the poor protec-
tion it affords as a vaccine is noteworthy. It
seems that, although not equally important
in virulence, all core epitopes are important
in inducing immunity. 
There are no studies on the efficacy of
the mutant B. abortus B2211 pgm as a vac-
cine and only data on their persistence.
Table V. Evaluation of O-polysaccharide (9.49, 2.17) and core (80.16, and 55.30) LPS mutants in
comparison with RB51 and S19 as vaccines against B. abortus and B. ovis infection in BALB/c
mice1.
Vaccine Dose (route) 4 Persistence (RT50 in weeks)
X log10 CFU in spleen ± SD 
(units of protection) of challenge strain 2,3
B. abortus 2308 B. ovis PA 
S19 1 × 105 (SC) 7.8 1.92 ± 0.65 (3.95) a, e 2.09 ± 1.83 (2.31) b, i 
RB51 1 × 108 (IP) 3.8 4.87 ± 0.19 (0.64) b, c 2.10 ± 2.29 (3.11) b, f 
9.49 per 1 × 108 (IP) 7.8 3.44 ± 1.37 (2.07) a, c, e 2.35 ± 2.51 (2.86) b, f, i 
2.17 wbkA 1 × 108 (IP) 7.8 3.27 ± 2.02 (2.24) a, c, e 0.61± 0.07 (4.60) a, f, i 
80.16 wa** 1 × 108 (IP) 3.8 5.24 ± 0.17 (0.27) b, c, f 4.07 ± 2.15 (1.14) c, e, i 
55.30 manBcore 1 × 108 (IP) 7.8 5.43 ± 0.26 (0.08) b, c, f 5.66 ± 0.32 (0.00) c, e, g 
Phosphate buffered 
saline
5.51 ± 0.12 5.21 ± 0.52
1
 Data are from Monreal et al. [78].
2
 Groups of 5 mice were vaccinated with the doses indicated, challenged IP 4 weeks later with either
B. abortus 2308 or B. ovis PA (both at 105 CFU/ mouse) and spleen CFU of the challenge strain were
determined two weeks later. Units of protection were calculated by subtracting the mean log10 CFU in the
spleens of vaccinated mice from the mean log10 CFU in the spleens of mice inoculated with phosphate
buffered saline.
3
 Statistical significance (Fisher Protected Least Significant Differences test): in comparison with phos-
phate buffered saline vaccinated group: a P = 0.05; b not significant; in comparison with S19 reference
vaccinated group: c P = 0.05; d not significant; in comparison with the RB51 vaccinated group: e P = 0.05;
f
 not significant.
4
 CFU administered subcutaneously (SC) or intraperitoneally (IP).
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BALB/c mice injected intraperitoneally
with 105 CFU of this mutant clear the
splenic infection in less than 2 weeks [126].
To compare this result with those obtained
with other core mutants in the above-sum-
marized studies is not possible owing to the
wide dose differences. However, this per-
sistence is much shorter than that of the
wboA mutants (see Sect. 6.1.3) which inoc-
ulated at a similar dose (5 × 105 CFU)
persisted for about 7 weeks [135]. As men-
tioned above, dysfunction of pgm affects (at
least) the LPS and the periplasmic β(1,2)
cyclic glucans which act as virulence fac-
tors [19]. On this basis, it can be speculated
that this mutant is overattenuated in mice.
6.2. Against B. melitensis and B. suis
The VTRM1 and VTRS1 mutants have
also been evaluated for their ability to pro-
tect mice against B. melitensis and B. suis
(biovars 1 and 4) in comparison with RB51,
S19 and Rev 1 [135]. The experiments
reproduced the results summarized above
(see Sect. 6.1.3): the protection achieved
with the S vaccines and VTRM1 and
VTRS1 was slightly better than that
obtained with RB51 and the best result was
obtained with the standard S vaccine. Pro-
tection against B. melitensis had been
observed before in RB51 vaccinated mice
by Jiménez de Bagüés et al. [60] but their
study did not include reference vaccine
strains for comparative purposes.
6.3. Against B. ovis
B. ovis is a naturally R species and,
although it lacks the O-PS characteristic of
the S Brucella species, it is virulent in
sheep. B. melitensis Rev 1 is the vaccine
currently used for B. ovis immunoprophy-
laxis but, since there is no role for anti
O-PS antibodies in protection in this case,
it can be predicted that R vaccines should
be more effective against B. ovis than
against S Brucella. RB51 was first tested
against B. ovis in the mouse model in the
experiments of Jiménez de Bagüés et al.
[60]. These authors observed that RB51
induced a protection against B. ovis com-
parable to that obtained against B. abortus
and B. melitensis (2.30, 2.03 and 1.72 pro-
tection units, respectively) but, as men-
tioned above, this study did not include S
vaccine strains for comparative purposes.
On the contrary, mutant VTRM1 has been
compared with Rev 1 [135], and the pro-
tection afforded against the B. ovis PA
strain was similar for both vaccines (1.92
and 1.58 protection units, respectively).
 The protective efficacy against B. ovis
of mutants 9.49 per, 2.17 wbkA, 80.16
wa**, and 55.30 manBcore has also been
studied in comparison with RB51 and S19
(Tab. V). Mutants 9.49 per and 2.17 wbkA
as well as S19 and RB51 afforded signifi-
cant protection with no statistically signif-
icant differences among them. However, it
was observed in these experiments that all
mice vaccinated with 2.17 wbkA cleared
the infection whereas 3 out of the 5 mice
vaccinated with 9.49 per, RB51 or S19
remained infected at slaughter [78]. In
parallel with the results obtained against
B. abortus, mutants with core defects did
not protect against virulent B. ovis, which
further supports the conclusion that an
intact core is required for maximal vaccine
efficacy in mice.
7. R VACCINES TESTED IN CATTLE
7.1. B. abortus 45/20
Vaccine 45/20 was used as a bacterin
about 25 years ago for controlling B. abor-
tus infection in cattle [84] and it was report-
edly useful in some European Union
countries [84, 106]. The standard condi-
tions in these countries were, however,
proficient sanitary services, intensive breed-
ing, good animal management practices and
low prevalence. Under these conditions, it
is extremely difficult to distinguish the
effect of the vaccine from the one that
would be caused by the sanitary measures
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by themselves, and experiences in other sit-
uations were much less favorable [84]. The
results of controlled experiments are satis-
factory in some cases but not in others [8,
84, 124], and direct comparisons with S19
unfavorable [8, 124]. Moreover, the quality
of the vaccine was a constant source of
problems [28]. The use of this vaccine was
abandoned when the problems in the sero-
logical tests associated to S19 vaccination
were considerably reduced by the develop-
ment of more specific serological tests, the
use of the conjunctival route of vaccination
and the demonstration of the usefulness of
the reduced S19 doses in adult cattle [84].
7.2. B. abortus RB51
7.2.1. Interference in S-LPS tests
As expected, 100% of the cattle subcu-
taneously vaccinated with RB51 develop
antibodies to R antigens that can be detected
in a dot ELISA and other tests [89, 91, 93,
95, 119]. On the contrary, vaccination with
RB51 does not significantly interfere in
classical tests such as the rose bengal, tube
agglutination and the complement fixation
test [21, 22, 45, 95, 117–119, 137]. Low
numbers of positive reactions in rapid
agglutination tests have been noticed after
RB51 revaccination of adults previously
vaccinated with S19 during calfhood but
the same sera were negative in confirma-
tory test [89]. Some authors have reported
that this revaccination induces antibodies
detectable in tube serum agglutination and
competitive ELISA in animals that had had
persistent reactions in rapid agglutination
tests [127] but others have not made this
same observation [111]. Classical tests use
suspensions of S brucellae where the LPS
core (shared totally or partially by S and R
brucellae) is not exposed and, therefore, the
anti R-LPS antibodies elicited by RB51 are
not detected. In immunosorbent tests with
S-LPS, or in tests using the LPS polysac-
charide obtained by acid hydrolysis, the
core epitopes (shared by the S and R LPS)
become accessible to antibodies. Moreo-
ver, it is well known that LPS extracts from
S brucellae always contain significant
amounts (up to 10%) of R-LPS normally
present in the surface of these bacteria. It is
therefore possible that R vaccines show
some degree of interference in these tests.
It has been repeatedly reported that the full
dose of RB51 in calves and the use of RB51
as a booster vaccine in adults that had been
vaccinated with S19 during calfhood do not
elicit antibodies detectable in the indirect
ELISA [45, 111, 117]. However, we have
observed that the indirect ELISA with
S-LPS is positive in a significant proportion
of RB51 vaccinated sheep and also in RB51
vaccinated cattle negative in the rose bengal
test (Marín C.M., Blasco J.M., Moreno E.,
unpublished results), which suggests that
attention should be paid to the standardiza-
tion of the S-LPS ELISA when vaccination
with RB51 is implemented. Two doses of
RB51 administered on a 30 day interval
have been reported to induce antibodies to
S B. abortus 99 detectable in a Coombs anti-
immunoglobulin test [23]. The specificity
of these antibodies has not been determined
with purified antigens and this protocol of
vaccination is unusual. The actual impor-
tance of these problems is not known and
they are possibly shared by all R vaccines.
7.2.2. Safety
As mentioned in the Introduction, S19
can induce abortion in a small proportion of
adult vaccinated cows (about 1% depend-
ing on the pregnancy status) and genital
problems in bulls. Thus, it is of interest to
know to what extent this problem could be
solved by any R vaccine. The experiments
in mice suggest that the abortifacient effect
of RB51 is reduced as compared to that of
S19 [112] but studies on bovine chorioal-
lantoic explants do not show differences
between the cytotoxicity of these two
strains [110].
In the natural hosts, the safety of a live
brucellosis vaccine (i.e. no shedding of the
viable vaccine and no abortifacient effects)
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depends on several factors. The most
important ones are the route and dose of
vaccination and the status and period of
pregnancy of the animals. The abortifacient
effect of live brucellosis vaccines becomes
apparent when the animals are vaccinated
during mid pregnancy (5–6 or 2–3 months
for cattle and sheep, respectively) since
there is a time interval (1.5–2 months in
both species) for the lesions leading to abor-
tion to develop. Shedding may happen via
vaginal excretion, aborted fetuses or milk.
RB51 is licensed (in the US) only for use
in young replacement animals at 1–3.4 ×
1010 CFU (full dose) by the subcutaneous
route [39]. Some authors have determined
the innocuousness of this dose adminis-
tered intramuscularly [39], but the protec-
tive efficacy of this method of vaccination
is unknown. Administered intravenously at
full doses in pregnant cattle, RB51 can
infect the bovine placenta, mammary
gland, and fetus, inducing placentitis and,
in some cases, delivery of premature and
weak calves [93]. This route represents a
severe test and is not used for vaccination,
but the results show that RB51 is not
exempt of risks. In fact, there is a reported
case of necrotizing placentitis and endometri-
tis with fetus colonization and abortion
caused in a pregnant heifer vaccinated with
the full dose of RB51 by the recommended
subcutaneous route [128]. The actual impor-
tance of this under field conditions cannot
be presently evaluated since there is a pau-
city of contrasted data in peer-reviewed
publications. Some authors claim that RB51
practically does not cause abortions in preg-
nant heifers when used at the full dose
[86] and, according to unpublished results
obtained by the manufacturer (cited in ref-
erence [88]), the vaccination of 624 preg-
nant cattle resulted in only one abortion and
milk excretion caused by the vaccine. Oth-
ers, however, have associated the use of
RB51 in 3–5 month pregnant cows in mass
vaccination trials in Chile with vaccine-
induced abortions and isolated this vaccine
from high numbers of aborted cattle and
also from cows at the moment of parturi-
tion [66]. The abortions took place 2.5–
3.4 months after vaccination with RB51
[66], an interval similar to that described in
abortions induced in sheep by B. melitensis
Rev 1 [17].
The use of a reduced dose (109 UFC) of
S19 in adult cattle lowers the rate of abor-
tion and milk excretion [84]. This idea has
been extrapolated to RB51, and it has been
shown that inoculation at 5 × 107 CFU is
safe [137]. However this highly reduced
dose (109 CFU is the proposed reduced
dose for adult vaccination with RB51)
seems too low to induce effective immu-
nity (see Sect. 7.2.3). In a comparative
study with a short number of animals (n =
5 in each group), neither RB51 nor S19
administered subcutaneously (9.4 and 3 ×
108 CFU, respectively) caused abortions
or placentitis lesions [95]. In two experi-
ments with 57 and 13 strain 19 calfhood-
vaccinated cattle, revaccination with the
reduced dose of RB51 did not also cause
abortion [111, 127]. However, the booster
vaccine (see Sect. 7.2.6) was applied in late
(7–8 months) pregnancy and this precludes
firm conclusions on the abortifacient effect.
In one of these experiments, RB51 was
excreted in milk by near the half (6/13) of
vaccinated cows, and in one case for up to
69 days after vaccination [127]. Obvi-
ously, the release of a bacterium carrying
rifampicin resistance into the environment
is of concern (see also Sect. 4.2).
7.2.3. Protection against B. abortus 
in controlled experiments
Table VI summarizes the results of the
five controlled experiments in which RB51
has been evaluated in cattle, either alone or
in comparison with the reference vaccine
S19, and which are susceptible to statistical
analysis. Experiments 1 (full dose, orally)
and 2 (reduced dose, subcutaneously) were
performed in adult cattle. Experiments 3, 4
and 5 were performed in groups of calves
vaccinated subcutaneously with the reduced
22 I. Moriyón et al.
(Experiment 3) or the full dose (Experi-
ments 3, 4 and 5). In two experiments (3 and
5), a comparison with S19 was made. In all
cases, the challenge strain was B. abortus
2308 and infection was defined by bacteri-
ological culture. In Experiment 1, however,
the bacteriological study was not as thor-
ough and timely as in the other experiments
(see footnotes of Tab. VI), a factor which
may bias the results.
The data presented in the original publi-
cations are analyzed in Table VII. The
parameters calculated are the etiologic frac-
tion (EF) and the relative risk (RR) of infec-
tion (and its 95% confidence interval) [73].
In the context of the experiments, the %EF
is the proportion of animals whose infection
is actually attributable either to the absence
of vaccination (when the non vaccinated
and vaccinated groups are compared) or to
the relative failure of a vaccine (when two
groups vaccinated with two different vac-
cines are compared). RR is the ratio
between the rate of infection in the non vac-
cinated versus vaccinated (either RB51 or
S19) or the RB51 versus S19 vaccinated
groups. According to these parameters, non
vaccinated animals have a 1.1 to 14.3 times
higher risk of becoming infected than RB51
orally vaccinated adult animals (Experi-
ment 1). It is worth noting that only 20% of
the RB51 vaccinated animals developed
Table VI. Summary of controlled experiments designed to evaluate RB51 in cattle.
Experiment 
[reference] Vaccine Dose Route
1 No. of 
animals2
Age at 
vaccination 
(months)
Vaccination-
challenge interval 
(months)
No.
infected 
(%)3
No. 
aborted 
(%) 
1 [41] RB51 ≥ 1 × 1010 OR 10 18 7.5 2 (20) 3 (30)
Saline OR 10 18 7.5 8 (80) 7 (70)
2 [88] RB51 1–3 × 109 SC 11 18 6 0 (0) 0 (0)
Saline SC 6 18 6 6 (100) 4 (67)
3 [87] RB51 1 × 109 SC 4 3–6 14–21 4 (100) 4 2 (50) 4
RB51 1 × 1010 SC 26 3–6 14–21 12 (46) 4 3 (11) 4
Saline SC 15 3–6 14–21 10 (67) 4 7 (47) 4
4 [22] RB51 1 × 1010 SC 29 3–10 12–21 3 (11) 4 n.d. 5
S19 1 × 1010 SC 22 3–10 12–21 1 (5) 4 n.d. 5
Saline SC 20 3–10 12–21 12 (60) 4 n.d. 5
5 [14, 15] RB51 1 × 1010 SC 24 9 9–14 20 (83.3) 4 n.d. 5
S19 1 × 1010 SC 29 9 9–14 18 (62) 4 n.d. 5
None SC 22 9 9–14 22 (100) 4 n.d. 5
1
 SC, subcutaneous; OR, oral.
2
 For Experiment 2, the groups vaccinated with 1 × 109 and 3 × 109 are pooled (see also text); for Expe-
riment 3, only the animals that could be necropsied and observed for abortion are included.
3
 In all experiments, infection was defined by bacteriological isolation of the challenge strain (B. abortus
2308 in all cases). In Experiment 1, the samples cultured were vaginal fluids and milk obtained at days 3
and 14 after parturition, and parotid, iliac and mammary lymph nodes obtained at necropsy but only in the
non-excretors 2 months after parturition; lungs and abomasal fluids of fetuses were also examined. In
Experiments 2, 3, 4 and 5, a thorough bacteriological search was performed which included (at least) sam-
ples of blood, milk, vaginal fluids, placenta and, after necropsy, mammary gland, spleen, liver, and the
most important lymph nodes.
4
 The figures are the pooled results of the different age groups in each experiment.
5
 n.d., no data (no or only part of the animals in the study were pregnant).
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antibodies to the vaccine, a result in clear
contrast with that obtained by the subcuta-
neous route (see Sect. 7.2.1). Although cor-
rect dosage and environmental safety may
be serious problems, the oral route has been
considered mostly as a possibility to vacci-
nate wildlife [41, 65] or small ruminants
under extensive management conditions in
semidesertic areas [83, 136]. The results
obtained with RB51 illustrate that routes
alternative to the subcutaneous one deserve
attention but because of the differences in
bacteriological procedures noted above, to
reach a clear conclusion on its usefulness to
administer R vaccines is not presently pos-
sible. Experiment 2 was also performed in
adult cattle but using a reduced subcutane-
ous dose and, although it is not possible to
calculate exact figures for RR, the EF for
this study was 100% and it is obvious that
the differences with the non vaccinated
group are very large. Surprisingly, the
reduced dose was totally ineffective in
calves (Experiment 3, Tab. VI). This con-
trast between Experiments 2 and 3 (reduced
dose) is striking, and there may be at least
two possible explanations. First, it is possi-
ble that the age at vaccination is decisive to
evoke a protective immune response by
RB51. On the basis of previous evidence, it
has been suggested [84] that the protection
given by S19 and 45/20 to adult cattle is
greater than that of cattle vaccinated as
calves and this could perhaps apply to the
results obtained with RB51. However,
when the evidence [8, 124] is examined it
becomes apparent that the comparisons
may be biased in favor of a more protective
effect in adults by the shorter time elapsed
between vaccination and challenge. Thus, a
second explanation for the discrepancies
observed between Experiments 2 and 3
(reduced dose) may lay in the different vac-
cination-challenge periods, which was at
least two times longer in the animals vacci-
nated at calfhood that were not protected
(Tab. VI).
The results obtained with the full dose of
RB51 in calves in the different experiments
is also apparently contradictory. Whereas
Experiments 3 (full dose) and 5 show no
significant differences between the RB51
Table VII. Etiologic fraction (EF) and relative risk (RR) calculated with the results of experiments
in which RB51 has been evaluated in cattle.
Experiment [reference] Comparisons RR (95% confidence interval) EF (%) P
1 [41] Saline versus RB51 (infection) 4.0 (1.1–14.3) 75 < 0.01
Saline versus RB51(abortion) 2.3 (0.8–6.5) 56 0.07
2 [88] Saline versus RB51 (infection) u.1 100 < 0.01
Saline versus RB51 (abortion) u.1 100 < 0.01
3 [87] Saline versus RB51 (infection) 2 1.4 (0.8–2.5) 31 0.20
Saline versus RB51 (abortion) 2 2.2 (0.8–5.8) 54 0.31
4 [22] Saline versus RB51 5.8 (1.9–17.9) 83 < 0.01
Saline versus S19 13.2 (1.9–92.6) 92 < 0.01
RB51 versus S19 2.3 (0.3–20.4) 56 0.60
5 [14, 15] No vaccine versus RB51 1.2 (1.0–1.4) 17 0.11
No vaccine versus S19 1.6 (1.2–2.1) 38 < 0.01
RB51 versus S19 1.3 (0.9 – 1.9) 25  0.16
1
 u., undefined.
2
 Only the figures of the full dose experiment were analyzed (in the reduced dose experiment, the % of
animals infected was higher in the vaccinated than in the control group).
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vaccinated and the non vaccinated groups,
in Experiment 4 the differences were sig-
nificant. As shown in Tables VI and VII,
the two experiments in which RB51 failed
to confer statistically significant protection
to calves had a higher percentage of infected
controls. Accordingly, as illustrated by the
grading RR and EF values derived from
these experiments (Tab. VII), the simplest
explanation for the apparent discrepancy
among Experiments 3, 4 and 5 is that the
immunity afforded by RB51 to calves is
progressively overcome as the challenge
efficacy (i.e. the number of controls infected)
increases. In contrast, the differences between
S19 vaccinated and non vaccinated calves
remain highly significant under both the
less (Experiment 3) and the most (Experi-
ment 4) stringent challenges, and the differ-
ences between S19 and RB51 become more
apparent in the most stringent experiment.
Experiment 4 is cited in the literature as the
demonstration that S19 and RB51 are sim-
ilarly effective in protecting cattle [68, 111,
113] but without a description of the partic-
ular experimental conditions (i.e. the low
% of infected controls) this presently seems
an overstatement. An additional point is
the apparent reduction (not statistically sig-
nificant) in abortions caused by RB51
(Tabs. VI and VII). Although this effect has
been suggested as a positive trait of RB51
even if infection is not prevented [86, 87],
it has to be kept in mind that, by itself, pro-
tection against abortion but not against
infection (and shedding) is not useful to
attain eradication (see Sect. 5.3).
7.2.4. Protection against B. abortus 
according to field experiments 
and observational studies
RB51 has been reported by Lord et al.
[68] to be much more effective than S19
under field conditions. In their study, sero-
logically negative calves (the Zebu type of
3 to 8 months of age) belonging to two
infected herds (one with 39% and the other
with 2% seroprevalence) were vaccinated
subcutaneously with the reduced dose (5 ×
109 CFU) of RB51 or S19 and kept in the
same herd for 240 days. The follow-up
consisted of serological testing using a
panel of 6 tests, including an agar immun-
odiffusion test with a Brucella polysaccha-
ride (native hapten or polysaccharide B)
and a rapid plate agglutination test. Used in
gel diffusion tests, this Brucella polysac-
charide precipitates with the sera of infected
but not S19 vaccinated cattle [33–35, 63,
67] even from heavily infected herds [63]
and positive results can thus be taken as an
index of infection. On the contrary, the
plate agglutination test is very sensitive but
not specific in differentiating infected from
S19 vaccinated cattle and is an index of
exposure (followed or not by infection) to
an S strain (either S19 or a field strain).
Also, some animals were bred to seroposi-
tive bulls and the abortions were recorded. 
A summary of the results of this field
experiment is presented in Table VIII.
They showed that RB51 was a much better
vaccine than S19, with a protection rate of
100% even in the herd with 39% seroprev-
alence or in the animals bred to seroposi-
tive bulls. These results are in marked
contradiction with those of the controlled
experiments in which comparisons with
S19 were made; none hinted at the superi-
ority of RB51 and, on the contrary, some
suggest or prove that S19 is a better vac-
cine when all parameters are made equal
for the groups tested and that the reduced
dose is not protective in calves. This field
experiment has a flaw in the selection
of the animals to be vaccinated. They
belonged to infected flocks and were cho-
sen on the basis of a negative serology, but
this method overlooks the fact that some
animals acquire latent infections not mani-
fested as a positive serology (reviewed in
reference [123]). It is, however, difficult to
see how this could have introduced a bias
in the selection of only one of the groups to
be vaccinated. It is also remarkable that
none of the RB51 vaccinated animals,
including those bred to seropositive bulls,
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became positive in the plate agglutination
test (Tab. VIII). This would be an expected
event since the controlled experiments
show that, when challenged, even the ani-
mals vaccinated with RB51 which do not
become infected develop a positive serol-
ogy in agglutination tests [22, 41, 87].
Figure 3 shows the results of observa-
tions carried out by one of us on five inde-
pendent dairy farms of the highlands of
Costa Rica. The farms were similar in that
replacement animals were kept in the same
herd in which they were born, reproduction
was always conducted through artificial
insemination and no purchase of external
replacements was made. Vaccine S19 was
applied subcutaneously at the full standard
dose until 1996 when the S19 reduced dose
(109 CFU) method was introduced. In
1999, S19 was replaced by RB51 (full
dose). No matter the vaccine, only young
replacement animals were vaccinated in all
herds. The sera of all aborted heifers had a
strongly positive result in the rose bengal
or serum agglutination and 2-mercaptoeth-
anol tests. Sera taken in year 2000 from
aborted cows were also tested in the com-
petitive ELISA (a test which is highly spe-
cific in detecting infected animals [85])
with positive results. Moreover, B. abortus
biovar 2 was isolated from aborted fetuses
surveyed in all five herds during the obser-
vational period. Due to economical con-
straints and to the fact that the rates of
abortion during the second and successive
pregnancies became low and tolerable by
farmers (the overall abortion rate in each
farm seldom reached 10% until year 2000),
seropositive animals were not removed
during the years in which S19 vaccination
was used. Figure 3 shows that the introduc-
tion of the reduced dose of S19 was fol-
lowed by a peak in the abortion rates of
first parturition heifers in most farms. It
can also be seen that the introduction of
RB51 did not improve the situation and
that, in fact, the percentage of abortions in
all farms was higher than in any of the pre-
ceding years. Although the results of
observations based on historical controls
are prone to be affected by confounding
factors, the simultaneous increase of abor-
tions in five independent farms in coinci-
dence with the replacement of S19 by
RB51 is remarkable.
7.2.5. Protection against B. melitensis
B. melitensis infection of cattle is
becoming a frequent finding in countries
with moderate or high prevalence of this
infection in small ruminants. Thus, an
effective vaccine in cattle should confer
protection against both B. abortus and
Table VIII. Summary of a comparative field evaluation of RB51 and S191.
Herd 
(% seroprevalence) Vaccine
No.
of animals
No. of animals (%) positive in: No. of dams aborted /
No. bred to seropositive 
bulls (%)RPAT 2 AGID 3
A (39) S19 75 23 (30.7) 8 (10.7) 11 / 20 (55.0)
RB51 140 0 (0.0) 0 (0.0) 0 / 44 (0.0)
None 40 18 (45.0) 18 (45.0) 18 / 20 (90.0)
B (2) S19 90 8 (8.9) 0 (0.0) 3 / 10 (30.0)
RB51 150 0 (0.0) 0 (0.0) 0 / 30 (0.0)
None 40 18 (45.0) 8 (20.0) 8 / 20 (40.0)
1
 Data are from Lord et al. [68].
2
 Rapid plate agglutination test.
3
 Agar gel immunodiffusion test with Brucella polysaccharide.
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B. melitensis. There are only limited studies
on the protection afforded by S19 against
B. melitensis in cattle, but they indicate that
S19 induces useful immunity [59]. No
information exists on the efficacy of RB51
against this heterologous infection.
7.2.6. RB51 as a booster vaccine
As discussed above (Sect. 7.2.3), it is
likely that the protection afforded by vac-
cination during calfhood wanes signifi-
cantly in a relatively short time. However,
repeated use of any classical S vaccine
would aggravate the problem of interpret-
ing the serological tests (see Sect. 1). On
these premises, revaccination with an effec-
tive R vaccine of animals previously vacci-
nated with an S vaccine could be interesting
since it would not booster antibody to the
S-LPS which would interfere in serodiag-
nosis. There are reports on RB51 use
(reduced dose) after calfhood vaccination
with S19 and data on the seroconversion in
different tests (see Sect. 7.2.1) [89, 111,
127]. The degree of reinforcement of
immunity achieved is not presently known.
A similar strategy would be the repeated
use of an R vaccine. This practice has been
implemented in northern Mexico where it
is recommended to vaccinate calves at
5 months, to revaccinate 6 months later and
to apply a third dose one year later. In case
of abortions, revaccination is recommended
[70]. According to a preliminary report, this
practice, combined with infected herd man-
agement measures, has led to a reduction in
prevalence from 30% to almost 0% in only
three years [70]. Indeed, this is an unprec-
edented result in brucellosis eradication
which calls for an urgent and detailed
description of the observations, including
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Figure 3. Evolution of abortion in first parturition heifers belonging to five independent B. abortus
(biovar 2) infected dairy farms (A to E) of the high lands of Costa Rica. The replacement heifers
were kept in the same farm in which they were born, reproduction was always conducted through
artificial insemination, and no purchase of external replacements was made in any herd. No positive
animal was culled through the years reported. Replacement heifers were vaccinated subcutaneously
with the standard dose of S19 until 1996 when the reduced dose was introduced. In 1999, S19 was
replaced by RB51 (full dose). The sera of all aborted heifers had a strongly positive serological
results (confirmed by competitive ELISA in year 2000) and B. abortus biotype 2 was isolated in all
five farms. 
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management procedures, costs and possi-
ble side effects of the vaccine.
7.3. B. abortus manBcore (rfbK ) mutant
This mutant was evaluated by Adams
et al. [2] in controlled experiments in cattle
in comparison with a reduced dose of S19
(Tab. IX). Both vaccines conferred signifi-
cant protection against a heavy B. abortus
challenge (all controls became infected).
Moreover, even under these stringent con-
ditions, there were no significant differ-
ences between the S19 vaccine and the
R mutant. The RR values for the unvacci-
nated versus S19 and RB51 are practically
identical (3.0 and 3.4 respectively [P <
0.001]) and differences between these vac-
cines are not significant (P = 0.3). On these
basis, this R mutant seems to be a very
promising vaccine. It has to be noted, how-
ever, that the report in which the experi-
ments are described [2] does not contain a
description of the bacteriological methods
used to define infection and that this is nec-
essary for a full appraisal of the results of
this work. It is also interesting to note that
a different R mutant in the same gene
(B. abortus 55.30 manBcore, see above) was
not protective in the mouse model (see
above) [78]. This could mean that Brucella
vaccine studies in the mouse model are
more limited than what it is generally
thought, but also that other R mutants such
as wbkA and per may be either not attenu-
ated enough or better R vaccines in cattle.
8. R VACCINES TESTED IN SHEEP 
Sheep can be infected by B. melitensis or
B. ovis and, in both cases, Rev 1 is the vac-
cine currently used [16, 17]. The safety of
RB51 in sheep has not been studied but
there are two controlled studies in which the
protective efficacy of RB51 and Rev 1 was
compared. In one (Tab. X), young rams
were vaccinated with either RB51 or Rev 1
and subjected to a severe B. ovis challenge
[61]. Then, the development of the genital
lesions characteristic of this infection were
recorded, and a thorough bacteriological
search for B. ovis was performed in thirteen
organs and lymph nodes to evaluate both
the protection and, in the infected rams, the
severity of infection (see Tab. X for details).
Under these stringent conditions, RB51
was neither able to protect the animals nor
reduced the severity of the infection or the
development of genital lesions. On the con-
trary, RR values (not shown) demonstrate
statistically significant differences between
Rev 1 and RB51 for protection (P < 0.05),
and between Rev 1 and unvaccinated con-
trols for both protection (P < 0.05) and
severity of infection (P < 0.01). Moreover,
El-Idrissi et al. [40] compared the ability of
RB51 and Rev 1 to protect sheep against
B. melitensis (Tab. XI). Even though the
challenge was not as severe as in the B. ovis
experiment (77% of infection in the non
vaccinated group), the performance of
RB51 was poor. RR values (not shown) for
the RB51 versus non vaccinated controls
Table IX. Comparison of vaccines S19 and manBcore (rfbK) R mutant against B. abortus in cattle1.
Vaccine Dose (CFU) 2 No. of animals No. infected (%) 3
manBcore (rfbK) R mutant 1 × 1010 24 7 (29)
S19 5 × 108 24 8 (33)
Saline 25 25 (100)
1
 Data are from Adams et al. [2]. The cows were challenged at 180 days of pregnancy with 1 × 107 CFU
of the virulent B. abortus 2308 strain given conjunctivally.
2
 Administered subcutaneously.
3
 Infection was defined by bacteriological isolation of the challenge strain from samples taken from
mothers and calves.
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are not significantly different (P = 0.67). On
the contrary, there are highly significant
differences in the RR values for the Rev 1
versus RB51 (P < 0.005), and Rev 1 versus
non vaccinated (P < 0.001) comparisons.
Similar conclusions are reached when the
figures of aborted fetuses and/or perinatal
deaths are analyzed.
9. R VACCINES TESTED IN GOATS
Three different R vaccines have been
tested in goats: RB51, the manBcore (rfbK)
mutant which was also tested in cattle (see
Sect. 7.3) and VTRM1. With regard to
safety, it has been reported that RB51 and
manBcore (rfbK) are not shed in the milk of
goats vaccinated with up to 4 × 1010 CFU
[114] and there is preliminary evidence
suggesting that they would not induce
abortion at the same dose [121]. Moreover,
there is one experiment in which three
fetuses were directly inoculated “in utero”
at 120 days of pregnancy with approxi-
mately 107 to 108 CFU of RB51 without
subsequent abortion, although vaginal excre-
tion was observed in one doe [108]. In
another study, the VTRM1 mutant did not
cause abortion when inoculated into six
goats at day 110 of pregnancy at a dose
of 1 × 1010 CFU [42]. In both studies,
Table X. A comparison of vaccines RB51 and Rev 1 for their ability to protect rams against
B. ovis1.
Vaccine No. of rams Dose (CFU)
No. infected (%) 2
No. with severe lesions
 (%)3Total Severely 
Rev 1 16 1.1 × 109 11 (69) 7 (69) 6 (38)
RB51 16 4.2 × 1010 16 (100) 15 (94) 13 (81)
None 15 15 (100) 15 (100) 9 (60)
1
 Data are from Jiménez de Bagüés et al. [61]. Rams were vaccinated subcutaneously at 6 months of age
and challenged 6 months later with 3 × 109 CFU (1 × 109 conjunctivally simultaneously with 1 × 109 pre-
putially) of B. ovis PA. 
2
 Infection was defined by bacteriological isolation of the challenge strain (spleen, testes, epididymes,
vesicular glands, bulbourethral glands, ampullae and seven lymph nodes were cultured). Rams that
showed at least one necropsy sample infected with ≥ 125 CFU of B. ovis were considered as severely
infected.
3
 Severe lesions were edema, interstitial fibrosis, epithelial hyperplasia, and widespread infiltration of
mononuclear and plasma cells.
Table XI. A comparison of vaccines RB51 and Rev 1 for their ability to protect sheep against
B. melitensis1.
Vaccine No. of ewes Dose (CFU) No. infected (%) 2 No. of aborted animals (%)
RB51 13 1.1 × 109 9 (69) 8 (62)
Rev 1 14 1.7 × 108 2 (14) 1 (7)
None 13 10 (77) 10 (77)
1
 Data are from El-Idrissi et al [40]. Ewes were vaccinated subcutaneously and challenged at 2–3 months 
of gestation with 5 × 107 CFU of virulent B. melitensis H38.
2
 Infection was defined by bacteriological isolation of the challenge strain (B. melitensis H38) from abor-
ted fetuses and/or vaginal fluids.
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however, the inoculations were performed
during late pregnancy (see Sect. 7.2.2) so
that no firm conclusions can be drawn on
the abortive effect of the vaccine.
There are only preliminary reports on the
protective effects of RB51 and manBcore(rfbK) and they are summarized in
Table XII. In Experiment 1 [121], RB51
and manBcore (rfbK) afforded protection
against a challenge that infected 60% of the
unvaccinated goats (RR values of this con-
trol versus the vaccines were 9.0 [P = 0.006]
and 4.5 [P = 0.028], respectively). It has to
be noted, however, that the experimental
protocol departs from others in that the ani-
mals had to be challenged twice before any
became positive in standard serological
tests (see footnotes of Tab. XII). This sug-
gests that the first challenge was ineffec-
tive, and it cannot be ruled out that this first
challenge may have had an immunizing
effect against the second challenge. In
Experiment 2 [55], RB51 was compared
with Rev 1. The number of animals in each
group was different and very limited in
some cases (Tab. XII). In contradiction
with the results of Experiment 1, Rev 1 but
not RB51 conferred significant protection
in this experiment (RRs of 8.0 [P = 0.05]
and 2.4 [P = 11], respectively, for the com-
parisons with the non vaccinated controls).
Thus, it seems clear that additional work is
necessary before solid conclusions could be
reached on the value of RB51 or manBcore(rfbK) for the prophylaxis of B. melitensis
in goats. There is also a report on the use-
fulness of VTRM1 (like RB51 a wboA
mutant) in goats [42]. When inoculated at
1010 CFU, VTMR1 persisted for two weeks
in the organs of the animals but longer times
were not studied. This vaccine does not
confer protection against infection whereas
Rev 1, even when used at very reduced
doses, is effective (Tab. XII).
10. R VACCINES TESTED IN SWINE
There have been numerous attempts to
develop a vaccine against porcine brucello-
sis (reviewed in reference [6]) but so far
none has been extensively used or clearly
Table XII. Summary of controlled experiments designed to evaluate R vaccines in goats.
Experiment 
[reference] Vaccine Dose (CFU)
1 No. of animals Challenge (CFU)2 No. infected (%)3
1 [121] RB51 4 × 1010 15 9 × 105 1 (7)
manBcore (rfbk) 1 × 109 15 9 × 105 2 (14)
Saline 10 9 × 105 6 (60)
2 [55] RB51 1 × 109 6 2 × 107 2 (33)
Rev 1 1 × 1010 10 2 × 107 1 (10)
Saline 10 2 × 107 8 (80)
3 [42] VTRM1 1 × 109 10 1 × 107 8 (80)
Rev 1 1 × 106 10 1 × 107 2 (20)
Saline 10 1 × 107 10 (100)
1
 Administered subcutaneously to adult animals.
2
 The challenge was applied conjunctivally in all experiments. In Experiment 1, a B. melitensis biovar 1 
field isolate was used and the animals challenged first at day 53 post vaccination and then at day 118 post 
vaccination, in both cases with the dose indicated in the Table. In Experiment 2, the animals were chal-
lenged with B. melitensis H38 three years after vaccination; and in Experiment 3, with B. melitensis 16M. 
All goats were conjunctivally challenged with 9 × 105 CFU of a virulent B. melitensis strain.
3
 In all experiments, infection was defined by bacteriological isolation of the challenge strain (B. abortus 
2308 in all cases). The organs cultured were: in Experiment 1, spleen, uterus, mammary gland and the 
most important lymph nodes; in Experiment 2, milk, uterus, mammary gland, spleen and lymph nodes; 
and in Experiment 3, spleen, liver and the most important lymph nodes. 
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been proven useful and, under most circum-
stances, depopulation is the only procedure
to control de disease. As an extension of
the field experiments in cattle described
above (see Sect. 7.2.4), RB51 has been used
in swine [69]. In this study, sows were
vaccinated with either RB51, a B. suis bac-
terin, or O-polysaccharide obtained from
B. abortus 1119–3 or B. suis 1330 by acid
hydrolysis. The animals belonged to a farm
with low seroprevalence (as judged by the
standard serological tests) and, in addition
to a possible accidental exposure, they were
mated to infected boars. The follow-up
consisted of serological testing (also using
the conventional tests) and in a bacteriolog-
ical examination of the abortions. Accord-
ing to these parameters, RB51 and the
O-polysaccharides, but not the B. suis bac-
terin, afforded full protection, regardless of
the dose (106 to 109 CFU, or 100 to 500 µg
of O-polysaccharide), the use of recall
doses (up to 3 injections) and the route
(intramuscular or oral). This total independ-
ence from route, dose and booster injections
is remarkable and, as the authors pointed
out, it is also noteworthy that two vaccines,
live attenuated RB51 and O-polysaccha-
ride, are similar in their protective capabil-
ity despite the fact that they differ greatly
in their composition. Indeed, the results
with the O-polysaccharide are particularly
intriguing since it is generally acknowledged
that O-polysaccharides derived from S-LPS
by acid hydrolysis behave as haptens and
the B. suis bacterin, which carries immuno-
genic O-polysaccharide, was ineffective.
Therefore, it seems that this set of remark-
able observations needs to be substantiated
in controlled experiments.
11. R VACCINES AND WILDLIFE
Brucella and/or antibodies to Brucella
antigens have been detected in a large vari-
ety of mammal species, including many
ungulates, lagomorphs, pinnipeds and ceta-
ceans. A major issue with respect to wildlife
brucellosis is whether the disease repre-
sents an occasional event not sustainable in
the absence of contact with the true hosts (as
in humans) or, on the contrary, it is perma-
nent [49]. In the second case, the disease
may have been established for a long time
(for example in marine mammals) or
resulted from relatively recent contact with
infected domestic livestock. When brucel-
losis is eradicated from the latter, suscepti-
ble wildlife may be a source of contagion
and vaccination may be a necessary meas-
ure in areas where these animals come in
contact with domestic livestock. There are
vaccination studies performed in American
bisons (Bison bison) and, to a lesser extent,
in elks (Cervus elaphus). There are also
data on the use of some Brucella vaccines
in reindeer (Rangifer tarandus), pronghorn
antelopes (Antilocapra americana), feral
swine (Sus scrofa) and coyotes (Canis lat-
rans). The reader is directed to the recent
and complementary reviews by Davis and
Elzer [30] and Godfroid [49] for a full
appraisal of the problems and approaches
involved, and only the main conclusions
regarding the use of R vaccines in wildlife
are summarized here.
Strain 19 is neither safe nor protective in
the American bison [30]. Thus, RB51 has
been tested in these animals but with con-
tradictory results. With regard to safety,
some authors report that RB51 causes both
lesions similar to those produced by S19
[90] and abortion of pregnant female
bisons [94]. Other studies do not substanti-
ate these findings [30, 92] and, also based
on some field observations, some authors
conclude that RB51 is relatively safe in
these animals [30]. Nevertheless, the pro-
tection afforded by RB51 seems nil in
adult bisons and the studies performed in
young female bisons are too limited to
draw firm conclusions [30].
The elks of the Greater Yellowstone
area often show antibodies to S Brucella,
and B. abortus has been isolated in some
cases [49]. In these animals, the situation
has been created by artificial feeding dur-
ing the winter, which increases the chances
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of contagion with other hosts coming to the
same feeding grounds. The efficacy of S19
in elks is presently unknown [30] but there
are studies on the protection provided by
RB51. Controlled experiments in captive
pregnant elks show that RB51, used either
in reduced or full doses, does not protect
against infection or abortion, even when
booster vaccine doses are applied [26].
12. CONCLUSION
Among the different approaches to solve
the problem of the interference of vaccina-
tion in the serodiagnosis of animal brucel-
losis, R vaccines represent an old but still
interesting alternative that has not found
either an optimal solution, nor a clear
answer to its actual usefulness. Strain RB51
is stable and attenuated, but the evidence
that it is equal or even better in terms of
safety and efficacy than S19 is conflictive.
In one field experiment subcutaneous vac-
cination of calves with reduced doses of
RB51 is reported to afford absolute protec-
tion, no matter the prevalence, and to per-
form better than S19. Good protection is
also reported in a controlled experiment in
adult cattle vaccinated orally with (pre-
sumably) the full dose of RB51 but the
bacteriological procedures used were not as
complete as those of other studies. Moreo-
ver, absolute protection is reported in a con-
trolled experiment in adult cattle vaccinated
subcutaneously with the reduced dose of
RB51. However, other controlled experi-
ments showed that this same reduced dose
and route is totally ineffective in calves.
Because the evidence on the efficacy of the
reduced dose of RB51 in adult cattle was
obtained by challenging the animals at a
time after vaccination shorter than that used
in the experiments with calves, it seems that
further experiments are necessary to test
the duration of immunity afforded by the
reduced dose. Other controlled experiments
strongly suggest or prove that calfhood vac-
cination with the full dose of RB51 is only
partially effective against moderate chal-
lenges. This is also supported by the obser-
vational study under conditions of high
prevalence presented here. Finally, depend-
ing upon the challenge, the available con-
trolled comparative experiments show that
S19 is a better vaccine than RB51. The evi-
dence on the usefulness of RB51 in sheep
and goats is either clearly negative or pre-
liminary and contradictory, respectively.
The possibilities of using RB51, or other
R vaccines, to booster immunity in adult
animals vaccinated with the classical vac-
cines, or the use of repeated doses of an
R vaccine deserve attention. However, evi-
dence on the usefulness of these possible
uses is not presently available. 
In all these uses of RB51, it is also
important to take into account the consid-
erations made in the Introduction about the
different contexts in which vaccination is
applied, and the goals attainable. The
desire of using a brucellosis R vaccine in
countries that have very low prevalence or
where control of brucellosis has been
achieved and eradication is feasible, is
understandable. However, at this point, the
use of the RB51 vaccine is questionable in
areas with moderate to high prevalence and
where serological diagnosis is performed
sporadically rather than on a regular basis,
only in herds devoted to trade or because
recurrent brucellosis is suspected. Under
these conditions, which are commonly
found in many low income countries, the
use of well established and tested vaccines
that have been demonstrated to be effective
tools for the control and eradication of bru-
cellosis for more than 60 years, must be
preferred over vaccines that have not been
thoroughly tested in comparative control-
led experiments. Nobody doubts the bene-
fits that a vaccine that avoids the conflict of
differentiating vaccinated over infected
animals will bring to all countries, but this
serological discrimination must be bal-
anced against protection, mainly in coun-
tries where serological diagnosis is not
performed on a regular basis.
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Despite the lack of agreement among
the experiments and the observations, and
despite the possible shedding of rifampicin
resistance genes into the environment,
RB51 has been recently approved in the
EU under the same conditions of use as in
the US (it has to be noticed that cattle bru-
cellosis was practically eradicated in the
US by the time of licensing) and it is being
used extensively in several Latin American
countries instead of S19. Several million
cattle have been vaccinated and, in some
countries, S19 is not available anymore so
that RB51 has become the obligatory vac-
cine [81]. However, there are no recorded
results accessible to analysis which may
substantiate claims on the benefits [70,
109, 113, 129] and not all these prelimi-
nary reports are favorable to RB51 [81]. A
future assessment of the real effects of
these massive vaccinations is likely to be
controversial because of the complexity of
the issues involved. They include not only
the multiple ways in which the vaccine is
being used (calfhood or adult vaccination,
vaccine doses, one or several doses, the
use of RB51 as a booster vaccine), often
beyond the conditions of the original
license (see Sect. 7.2.2), the effect of
prevalence, the problems associated with
delimiting the effects of the vaccine and of
sanitary measures, or with obtaining relia-
ble data in areas where breeding is exten-
sive and official veterinary services scarce,
but also political and economical interests.
Brucellosis may seem to be a straightfor-
ward disease from a textbook but it is very
complicated in the field and that is why
conclusive controlled experiments should
be mandatory before eradication enter-
prises are undertaken. 
More recently developed R mutants
may offer improved alternatives, including
better protective efficacy and removal of
the mutated genes and antibiotic markers.
Although the evidence is limited to a single
experiment in cattle, B. abortus manBcore(rfbK) seems promising. Other candidates,
such as the wbkA and per R mutants per-
form better than RB51 or manBcore (rfbK)
in mice. This suggests that R vaccines
could be more efficient when the mutations
involved in generating the R phenotype are
such that the LPS core structure remains
unscathed and carries no additional muta-
tions elsewhere in the genome. The actual
attenuation, safety and efficacy in the nat-
ural hosts of these mutants remain to be
studied. A full understanding of the genet-
ics and structure of the Brucella LPS, and
of its precise role in the intracellular
behavior of this pathogen, should provide a
better basis for developing both better lab-
oratory models and more effective vac-
cines. 
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